期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 369, 期 19, 页码 1852-1853出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMe1311325
关键词
-
More than a decade ago, imatinib, an agent that has a specific inhibitory interaction with the BCR-ABL fusion protein, was introduced for the treatment of chronic myeloid leukemia (CML). The introduction of this agent dramatically changed researchers' understanding not only of the role of tyrosine kinases as targets for oncology drugs (despite the conserved status of protein kinase domains in nature), but also their ability to conceptualize and test novel molecular mechanisms of action and drug resistance in solid tumors such as adenocarcinoma of the lung as well as in hematopoietic cancers.(1),(2) The underlying genetic instability of most cancers ...
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据